-+ 0.00%
-+ 0.00%
-+ 0.00%

bioAffinity quarterly CyPath Lung test sales double, up more than 200% year over year

PUBT·07/07/2026 12:46:54
Listen to the news
bioAffinity quarterly CyPath Lung test sales double, up more than 200% year over year
  • bioAffinity Technologies reported Q2 2026 CyPath Lung test sales up more than 30% from Q1 2026, doubling to a new quarterly record.
  • Q2 tests sold rose more than 200% from Q2 2025, extending year-over-year growth above 200%.
  • Nearly 3,000 CyPath Lung tests have been performed since commercial launch, reflecting broader adoption across pulmonology and medical-center settings.
  • Financial results for Q2 2026 are scheduled for release in August.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707410622) on July 07, 2026, and is solely responsible for the information contained therein.